Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?

Seminars in Hematology

Volumn 47, Issue 4, 2010, Pages 344-353

  Jabbour, Elias ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; AP 24534; BCR ABL PROTEIN; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; NILOTINIB; OMACETAXINE MEPESUCCINATE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; PANCREATITIS; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PLEURA EFFUSION; POINT MUTATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 77957096041     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.06.002     Document Type: Article

References (61)

1. Ramchandren R., Schiffer C.A. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. Biologics Targets Ther 2009, 3:205-214.
2. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 1999, 340:1330-1340.
3. Schiffer C.A. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007, 357:258-265.
4. Jabbour E., Cortes J., Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Targ Oncol 2009, 4:3-10.
5. Alvarez R.H., Kantarjian H., Cortes J.E. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007, 44:S4-S14.
6. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497-1504.
7. Rowley J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
8. Quintas-Cardama A., Cortes J.E. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006, 81:973-988.
9. Cortes J., O'Dwyer M.E. Clonal evolution in chronic myelogenous leukemia. HematolOncol Clin North Am 2004, 18:671-684.
10. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
11. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
12. Wong S.F. New dosing schedules of dasatinib for CML and adverse event management. J Hematol Oncol 2009, 2:10.
13. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
14. Gleevec 2009, [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ.
15. Deininger M., O'Brien S.G., Guilhot F., et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114:1126. [abstract].
16. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients 534 receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
17. Clinical practice guidelines in oncology. Chronic Myelogenous Leukemia. V.2.2010 National Comprehensive Cancer Network (NCCN), Accessed September 24, 2009. http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf.
18. Lee F., Fandi A., Voi M. Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 2008, 40:334-343.
19. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
20. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCRABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-1773.
21. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
22. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928-1937.
23. 2009. NccnNCpgioCMLV.
24. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
25. Hughes T., Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006, 20:29-41.
26. Kantarjian H., O'Brien S., Shan J., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. Cancer 2008, 112:837-845.
27. Quintas-Cardama A., Kantarjian H., Jones D., et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009, 113:6315-6321.
28. Kantarjian H.M., Larson R.A., Guilhot F., et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009, 115:551-560.
29. Jabbour E., Kantarjian H., O'Brien S., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 2008, 113:2154-2160.
30. Sprycel (dasatinib) 2007, Bristol-Myers Squibb, Princeton, NJ, [package insert].
31. Dasatinib prescribing information May 2008, Bristol-Myers Squibb, Princeton, NJ.
32. Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109:2303-2309.
33. Cervantes F., Baccarani M., Lipton J., et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C study. Haematologica 2008, 93:372.
34. Kantarjian H., Pasquinin R., Levy V., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
35. Shah N.P., Kim D.W., Kantarjian H.M., et al. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034. J Clin Oncol 2007, 25:358s.
36. Kantarjian H., Cortes J., Kim D.W., et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009, 113:6322-6329.
37. Larson RA, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 Mg twice daily (BID) in patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035. Abstract 2926. Presented at: 50th ASH Annual Meeting. San Francisco, CA; December 6-9, 2008.
38. Saglio G, Kantarjian HM, Hochhaus A, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035. Abstract 3226. Presented at: 50th ASH Annual Meeting. San Francisco, CA; December 6-9, 2008.
39. Tasigna 2009, Novartis Pharmaceuticals Corp, East Hanover, NJ, [package insert].
40. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
41. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
42. Deininger M.W. Nilotinib. Clin Cancer Res 2008, 14:4027-4031.
43. Kantarjian H., Giles F., Bhalla K., et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. Blood (ASH Annual Meeting Abstracts) 2009, 114:1129. [abstract].
44. Hochhaus A., Giles F., Apperely J., et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study. Abstract: 0631. Haematologica 2009, 94(suppl 2):256. Presented at: 14th Congress of the European Hematology Association; June 4-7, 2009; Berlin, Germany.
45. Cortes J., Kantarjian H.M., Kim D.-W., et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. ASH Annual Meeting Abstracts 2008, 112:1098.
46. Cortes J., Talpaz M., Deininger M., et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations. Blood 2009, 114:643. [abstract].
47. Cortes-Franco J., Khoury H.J., Nicolini F.E., et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter phase 2/3 study. Blood 2009, 114:644. [abstract].
48. Cortes-Franco J, Raghunadharao D, Parikh P, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors: results of a multicenter phase 2/3 study. Abstract 861. Program and abstracts of the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA.
49. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
50. Alvarado Y, Kantarjian H, O'Brien S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
51. Cortes J., Jabbour E., Kantarjian H., et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007, 110:4005-4011.
52. Jabbour E., Kantarjian H., Jones D., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008, 112:53-55.
53. Jabbour E., Jones D., Kantarjian H.M., et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009, 114:2037-2043.
54. Soverini S., Martinelli G., Colarossi S., et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. Blood 2006, 24:e51-e52.
55. Jabbour E., Kantarjian H.M., Jones D., et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008, 112:4839-4842.
56. Müller M.C., Cortes J.E., Kim D.-W., et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. Blood 2009, 114:6914-6915.
57. Kantarjian H.M., Jabbour E., Giles F.J., et al. Prognostic factors for progression-free survival in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24 month data. Blood 2009, 113:3298.
58. Jabbour E., Kantarjian H., O'Brien S., et al. Predictive factors for response and outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure. Abstract 509. Blood 2009, 114:210.
59. Quintas-Cardama A., Kantarjian H., O'Brien S., et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007, 25:3908-3914.
60. Lipton J.H., Sriharsha L., Bogomilsky S., et al. Pleural effusions in patients treated with dasatinib: Results from two institutions, risk factors and management. J Clin Oncol 2007, 25:680s.
61. Carpiuc K.T., Stephens J.M., Liou S.Y., et al. Incidence of grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CP-CML): a comparison of nilotinib and dasatinib. J Clin Oncol 2007, 25:17501. [abstract].